Methadone Treatment for Opioid Use Disorder: Improving Access Through Regulatory and Legal Change: Proceedings of a Workshop
| Autor: | Stroud C, Posey Norris SM, Bain L |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | 2022 Jul 15. |
| DOI: | 10.17226/26635 |
| Abstrakt: | Methadone is a Food and Drug Administration- (FDA-) approved medication for treating opioid use disorder (OUD), a chronic brain disease that affects more than 2.7 million people in the United States aged 12 and older. Despite its effectiveness in saving lives, many barriers impede access to, initiation of, and retention in methadone treatment for OUD. To address these barriers, on March 3 and 4, 2022, the National Academies of Sciences, Engineering, and Medicine hosted a workshop on “Methadone Treatment for Opioid Use Disorder: Examining Federal Regulations and Laws,” at the request of the Office of National Drug Control Policy in the Executive Office of the President. This publication summarizes the presentation and discussion of the workshop. (Copyright 2022 by the National Academy of Sciences. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|